Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Capital One has retraced roughly 27% from its January highs, trading near $185 and offering an attractive risk-reward for a tactical long. The Discover acquisition and targeted $2.7B of synergies, improving auto loan performance, strong free cash flow, and a modest balance sheet give the company room to reclaim lost ground. I recommend a mid-term s…
Progressive has engineered industry-leading premium growth and underwriting results. With a market cap near $119B, a P/E around 10x and strong free cash flow, the stock looks actionable on a mid-term rebound. Expect underwriting margins to normalize from cyclical highs, but continued share gains, telematics advantages, and investment income should …
Revolution Medicines delivered a landmark Phase 3 RASolute 302 result for daraxonrasib that doubled median overall survival in previously treated metastatic pancreatic cancer and produced a 60% reduction in risk of death. That clinical leap turns a clinical-stage oncology name into a commercial opportunity. We upgrade our stance to a tactical long …
Ares Management (ARES) has been punished alongside private-credit peers on liquidity fears. The company’s diversified fee streams, solid free cash flow of $1.59B, and a current dividend that pays out roughly $5.40 annually per share argue the pullback overstates structural risk. We outline a mid-term trade: buy into weakness with a $135 entry, a $1…
Prime Medicine has moved from promise to early clinical proof with prime editing data and a NEJM publication for PM359. At a market cap near $500M and a cash runway into 2027, the stock offers an asymmetric payoff if additional programs validate. This trade idea outlines a long entry with strict risk controls and key catalysts to watch.
WhiteFiber is uniquely positioned in the AI infrastructure market after securing multi-year colocation capacity deals. With a market cap near $950M, constrained float and rising utilization, the stock has asymmetric upside into prior highs if execution continues. This trade targets a move toward $36 in the next 45 trading days with a disciplined st…
CMB.TECH has strengthened its fleet and is benefiting from elevated freight rates tied to shipping disruptions, but the stock trades well above last summer's lows and already reflects a meaningful recovery. We prefer a measured, swing-oriented long with clearly defined risk controls: enter at $15.50, target $17.50 and stop $13.80 for a mid-term tra…
SouthState Bank Corporation has shown consistent profitability, low leverage and tangible scale gains from recent M&A. With a P/E near 10.5, a 2.4% dividend yield and an improving technical setup, SSB warrants an upgrade to a constructive stance. This trade idea lays out an entry, stop and target for a long-term (180 trading days) position while hi…
Workday's accelerating AI adoption (agentic AI up ~200% y/y and nearing $500M ARR) paired with a free cash flow yield north of 9% creates a workable trade: buy into the AI-driven re-acceleration at modest FCF multiples, with a tight stop and a 30%+ upside target over the next 45 trading days.
AppLovin's recent beats and accelerating conversion rates are translating into both revenue growth and outsized margins. At a market cap near $167B and a P/E around 42x, the stock already prices optimism, but the combination of product-led ad performance gains, AI-enabled targeting, and manageable short interest sets up a disciplined long trade wit…
Millicom (TIGO) combines a rare growth path for a telecom with a 3%+ dividend yield. Recent acquisitions and improving equity free cash flow create room for multiple expansion while the balance sheet target (2.5x leverage) keeps risk contained. Trade plan provided for a mid-term (45 trading days) position.
Nanobiotix (NANO) is a specialty biotech with a physics-based radioenhancer platform and an underappreciated royalty engine. The setup today favors a directional long: modest entry risk for substantial upside if near-term clinical/regulatory catalysts and royalty monetization materialize. Trade plan below targets a 45-trading-day horizon with clear…
EZJ (ProShares Ultra MSCI Japan) offers leveraged access to a Japan rally that’s outpacing the U.S. The ETF is trading near $64, sits above short- and medium-term moving averages, and carries a small market cap of $14.08M plus a modest quarterly distribution. This is a tactical, high-risk long trade: entry $64.02, stop $59.00, target $70.50, horizo…
Northland Power's advanced-stage wind and solar projects look materially discounted relative to the probability-weighted cash flows they represent. With several projects at or near financial close and long-term offtake for a sizable portion of expected output, the market has priced in execution failure and higher-for-longer rates. We believe the st…
Silence Therapeutics (SLN) is a $313M market-cap RNA therapeutics company trading near $6.73. We see an asymmetric risk/reward into an August 2026 Divesiran data readout and a recent strategic pivot in the Zerlasiran program. Positive Divesiran data plus a clearer commercialization path for Zerlasiran could fast-track a re-rating versus peers. We r…
Centene (CNC) has moved from a $25 low last year to the mid-$60s on better-than-expected reimbursement dynamics and improving operational leverage. The fundamentals are mixed — negative GAAP EPS and membership headwinds remain — but valuation is compelling and free cash flow is strong. This trade idea targets a measured swing long with clear entry,…
Seneca Foods (SENEA) is a cash-generative packaged-fruit-and-vegetable company trading near its 52-week high after a strong run. At a market cap of roughly $1.14B and free cash flow of $168.5M, the stock looks reasonably valued (PE ~11.5, EV/EBITDA ~7.4). This trade targets continued multiple expansion and frozen-segment recovery over the next 45 t…
L.B. Foster (FSTR) has more than doubled from its 52-week low and is sitting near $42 with accelerating volume, improving margins and free cash flow of $40.5M. The rail and infrastructure end-markets are driving outsized segment growth, and the balance sheet can support further organic growth and shareholder-friendly outcomes. This trade idea outli…
One Stop Systems (OSS) is a niche, high-performance edge compute vendor that just reported a string of defense and commercial wins. With $15M in new bookings (including a $10.5M Navy award), Q1 revenue beat and guidance for 20-25% growth in 2026, the stock is carving out a new growth chapter. This trade idea proposes a long position with a $16.60 e…
Clarus Corporation ($CLAR) is a compact outdoor-equipment operator with recognizable brands, no debt, and a market cap under $120M. That profile creates takeover optionality while the operational picture remains mixed. We lay out a long trade for investors who want to play a potential buyout or a continued operational recovery with a clear entry, s…
Fidelity National Financial (FNF) trades at roughly $47.87 with a market cap near $12.9B, a P/E around 17 and free cash flow of roughly $5.45B. Combine recurring title-insurance margins, accelerating F&G annuities and a reliable quarterly dividend ($0.52) and you get an actionable long setup into 2026. The trade: enter $48.00, stop $43.50, target $…
LightPath Technologies (LPTH) has structural positives — a pivot toward infrared and defense optics, a recent financing that stabilized the balance sheet, and improving technical support above the $14–$16 zone. This trade idea outlines an actionable long with a clear entry at $15.00, a $13.00 stop loss, and a $22.00 target over a 180 trading-day ho…
Comcast (CMCSA) is a mixed fundamental story: secular pressure in broadband subscribers and ad cyclicality in Media, offset by very attractive valuation metrics (P/E ~4.7, P/FCF ~4.2, EV/EBITDA ~4.8) and $20.4B in free cash flow. This trade idea recommends a long entry near $24.32, a conservative stop at $21.50, and a target of $30.00 on a long-ter…
Boston Scientific (BSX) has been punished hard in 2026 despite healthy free cash flow, manageable leverage and tangible product catalysts. The market is pricing the company as a broken compounder; we argue that upcoming clinical readouts and the MiRus TAVR stake provide a credible reset. This is a mid-term swing trade idea with a clearly defined en…
Alphabet's dominant search franchise, expanding cloud footprint, and ongoing AI investments create a compelling risk/reward for a mid-term long. Valuation sits at ~27x earnings with $64.4B in free cash flow and a $4.37T market cap. This trade plan targets a move back toward prior highs while protecting capital if AI spending or macro liquidity pres…
